Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 2,513 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Scar
Interventions: Laser treatment; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Miami, Florida • Plantation, Florida

Conditions: Obesity, Childhood
Interventions: Low sugar and carbohydrate diet, Time Limited Eating, Continuous Glucose Monitor; Behavioral · Device
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 14 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus
Interventions: Experimental Group instructions for glucose management via App, Placebo Comparator general instructions; Other
Lead sponsor: Marshall University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Huntington, West Virginia

Conditions: Decreasing Destructive Behavior, Increasing Functional Communicative Behavior
Interventions: Traditional Schedule Thinning, PIA-Informed Schedule Thinning, PIA-Informed Schedule Thinning with Competing Stimuli; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 3 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Somerset, New Jersey

Conditions: Healthy
Interventions: rTMS; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Plague, Plague, Bubonic, Plague, Pneumonic, Yersinia Pestis Plague, Yersinia Pestis; Bubo, Yersinia Pestis; Pneumonia, Yersinia Sepsis, Yersinia Pestis Infection, Bubo; Yersinia Pestis, Bubonic; Plague, Skin, Pneumonic Plague
Interventions: Lateral Flow Assay for Pathogens of the Plague; Diagnostic Test
Lead sponsor: Brimrose Technology Corporation; Industry
Eligibility: 5 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Amputation
Interventions: Prosthetic Foot Emulator, Commercially available prosthetic feet; Device
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 89 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Minneapolis, Minnesota • San Antonio, Texas • Seattle, Washington

Conditions: Keratitis, Corneal Ulcer
Interventions: Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears; Combination Product · Other
Lead sponsor: Peschke GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 468 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more

Conditions: Infertility
Interventions: Vitrification medium oocyte, warming medium oocyte and Rapid-i; Device
Lead sponsor: Vitrolife; Industry
Eligibility: 18 Years to 37 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Dallas, Texas • Frisco, Texas

Conditions: Healthy Volunteer
Interventions: Treatment A: Naloxone Nasal Spray, Treatment B: Naloxone Nasal Spray, Treatment C: Naloxone HCL Intramuscular (IM) Injection; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Skin Diseases
Interventions: Not listed
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Hospital Acquired Condition
Interventions: The Beat Analytics System (BAS); Device
Lead sponsor: Bob Topp; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Peripheral Vascular Disease
Interventions: Gelfoam/Thrombin, VascuSeal; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Non-interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Beverly Hills, California • Gainesville, Georgia • Coeur d'Alene, Idaho + 4 more

Conditions: Healthy Volunteers, Speech
Interventions: Altered Auditory Feedback (AAF), Visual-Acoustic Biofeedback; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Chest Pain, Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease
Interventions: CT Coronary Angiography (CTCA), Traditional Strategy; Diagnostic Test · Procedure
Lead sponsor: American College of Radiology; Other
Eligibility: 30 Years and older
Enrollment: 1,392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Winston-Salem, North Carolina • Hershey, Pennsylvania • Philadelphia, Pennsylvania + 1 more

Conditions: Viral Infection
Interventions: Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3; Biological
Lead sponsor: AlloVir; Industry
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Liver Diseases, Healthy
Interventions: Zongertinib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hematologic Disorders, Oncologic Disorders, Rheumatologic Disorders
Interventions: Rituximab; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 19 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: SARS-CoV-2 Acute Respiratory Disease, Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Post-acute Sequelae of SARS-COV-2 Infection, Post COVID-19 Condition
Interventions: Extension for Community Healthcare Outcomes; Other
Lead sponsor: Family Health Centers of San Diego; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Multi-drug Resistant Tuberculosis
Interventions: Pretomanid; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Sepsis, Deterioration, Clinical, Critical Illness, Early Warning Score
Interventions: Algorithm-triggered sepsis alert with structured critical care team activation; Other
Lead sponsor: Patricks Lyons; Other
Eligibility: 18 Years and older
Enrollment: 3,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Keratoconus, Ocular Surface Disease, Pellucid Marginal Corneal Degeneration, Ectasia, Corneal Trauma, Corneal Scar, Dry Eye Syndromes, Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions: Ocular surface optical coherence tomography; Device
Lead sponsor: Boston Sight; Other
Eligibility: 21 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: Hodgkin Disease
Interventions: ABVE-PC, DECA; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Evaluation of Non-Ablative Laser for Treatment of Direct Brow Lift Scars

Time Limited Eating in Adolescents (Time LEAd): a Pilot Study

Glycemic Emergency Management (GEM); An App for Rapid Response to Hypoglycemic and Hyperglycemic Situations

Motivational Refinements for Facilitating Reinforcement Schedule Thinning

Metaplasticity Experimental Design and Comparison of Motor Outcome Measure Sensitivity to Change

Yersinia Pestis Lateral Flow Immunoassay for Blood Samples

A Test-Drive Strategy for the Prescription of Prosthetic Feet for People With Leg Amputations

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers

Performance Study of New Media for Vitrification of Human Oocytes

A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers

Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis

The Effect of Real Time Analytics on Adverse Events Among Hospitalized Patients

Study to Evaluate Safety & Effectiveness of Vascular Sealant System

The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

Prediction of Visual Feedback Effects on Speech Motor Adaptation in Healthy Adults

Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)

ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders

Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

Hospital-Onset Sepsis Systematic Detection and Structured Interventions

Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting

Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A